Wang Wei-Feng, Yang Lin-Hong, Han Lin, Li Ming-Jun, Xiao Jian-Qi
Department of Neurosurgery.
Department of Otorhinolaryngology, First Affiliated Hospital of Jiamusi University.
Medicine (Baltimore). 2019 Feb;98(6):e14434. doi: 10.1097/MD.0000000000014434.
This systematic review aims to assess the efficacy and safety of transsphenoidal surgery (TPS) for patients with a pituitary tumor (PT).
We will retrieve the following electronic databases for randomized controlled trials or case-control studies to assess the effect and safety of TPS for PT: Cochrane Library, EMBASE, MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Allied and Complementary Medicine Database, and Chinese Biomedical Literature Database. Each database will be retrieved from the inception to December 20, 2018. The entire process consists of the study selection, data collection, methodology quality assessment, data pooled, and meta-analysis performance. The methodology quality will be assessed by using Cochrane risk of bias tool. The data pooled and meta-analysis will be conducted by using RevMan 5.3 software.
This study will evaluate the efficacy and safety of TPS for PT. The primary outcome includes total tumor resection rate. The secondary outcomes consist of quality of life, total tumor resection rate, postoperative complication rate, and the rate of functional tumor hormone levels.
The expected results may provide up-to-date evidence of TPS for the treatment of PT.
PROSPERO CRD42018120194.
本系统评价旨在评估经蝶窦手术(TPS)治疗垂体瘤(PT)患者的疗效和安全性。
我们将检索以下电子数据库以获取随机对照试验或病例对照研究,以评估TPS治疗PT的效果和安全性:Cochrane图书馆、EMBASE、MEDLINE、护理学与健康相关文献累积索引、科学网、补充与替代医学数据库以及中国生物医学文献数据库。每个数据库将从建库至2018年12月20日进行检索。整个过程包括研究选择、数据收集、方法学质量评估、数据合并及荟萃分析。方法学质量将使用Cochrane偏倚风险工具进行评估。数据合并及荟萃分析将使用RevMan 5.3软件进行。
本研究将评估TPS治疗PT的疗效和安全性。主要结局包括肿瘤全切除率。次要结局包括生活质量、肿瘤全切除率、术后并发症发生率以及功能性肿瘤激素水平发生率。
预期结果可能为TPS治疗PT提供最新证据。
PROSPERO注册号:PROSPERO CRD42018120194。